Enzymotec Ltd. (NASDAQ:ENZY)’s share price traded up 0.8% during trading on Tuesday after Wells Fargo & raised their price target on the stock from $9.50 to $12.00. Wells Fargo & currently has a market perform rating on the stock. Enzymotec traded as high as $11.85 and last traded at $11.75. 980,046 shares traded hands during trading, an increase of 673% from the average session volume of 126,818 shares. The stock had previously closed at $11.85.

Several other equities analysts have also recently commented on ENZY. ValuEngine raised shares of Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Jefferies Group LLC reaffirmed a “hold” rating and set a $11.50 price target on shares of Enzymotec in a research report on Thursday, October 19th. Finally, Zacks Investment Research raised shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Four equities research analysts have rated the stock with a hold rating, The stock has a consensus rating of “Hold” and a consensus price target of $11.75.

Several hedge funds have recently modified their holdings of the company. Osborn Williams & Donohoe LLC bought a new position in shares of Enzymotec during the third quarter worth about $137,000. State Street Corp lifted its position in shares of Enzymotec by 1.8% during the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 380 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Enzymotec during the second quarter worth about $2,350,000. 27.20% of the stock is currently owned by institutional investors and hedge funds.

Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.15). The company had revenue of $13.00 million during the quarter, compared to analyst estimates of $12.78 million. Enzymotec had a negative return on equity of 3.88% and a negative net margin of 14.52%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.04 earnings per share.

COPYRIGHT VIOLATION NOTICE: “Enzymotec Ltd. (ENZY) Trading -0.8% Higher Following Analyst Upgrade” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/enzymotec-ltd-enzy-trading-0-8-higher-following-analyst-upgrade/1671886.html.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.